HCPCS Level II › C
HCPCS Level II codes starting with C
622 codes, page 4 of 7. Every code ever valid for billing is listed, including those now retired.
| Code | Description | Status |
|---|---|---|
| C9014 | Injection, cerliponase alfa, 1 mg through FY2026 | Terminated |
| C9015 | Injection, c-1 esterase inhibitor (human), haegarda, 10 units through FY2026 | Terminated |
| C9016 | Injection, triptorelin extended release, 3.75 mg through FY2026 | Terminated |
| C9021 | Injection, obinutuzumab, 10 mg through FY2026 | Terminated |
| C9022 | Injection, elosulfase alfa, 1mg through FY2026 | Terminated |
| C9023 | Injection, testosterone undecanoate, 1 mg through FY2026 | Terminated |
| C9024 | Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine through FY2026 | Terminated |
| C9025 | Injection, ramucirumab, 5 mg through FY2026 | Terminated |
| C9026 | Injection, vedolizumab, 1 mg through FY2026 | Terminated |
| C9027 | Injection, pembrolizumab, 1 mg through FY2026 | Terminated |
| C9028 | Injection, inotuzumab ozogamicin, 0.1 mg through FY2026 | Terminated |
| C9029 | Injection, guselkumab, 1 mg through FY2026 | Terminated |
| C9030 | Injection, copanlisib, 1 mg through FY2026 | Terminated |
| C9031 | Lutetium lu 177, dotatate, therapeutic, 1 mci through FY2026 | Terminated |
| C9032 | Injection, voretigene neparvovec-rzyl, 1 billion vector genome through FY2026 | Terminated |
| C9033 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg through FY2026 | Terminated |
| C9034 | Injection, dexamethasone 9%, intraocular, 1 mcg through FY2026 | Terminated |
| C9035 | Injection, aripiprazole lauroxil (aristada initio), 1 mg through FY2026 | Terminated |
| C9036 | Injection, patisiran, 0.1 mg through FY2026 | Terminated |
| C9037 | Injection, risperidone (perseris), 0.5 mg through FY2026 | Terminated |
| C9038 | Injection, mogamulizumab-kpkc, 1 mg through FY2026 | Terminated |
| C9039 | Injection, plazomicin, 5 mg through FY2026 | Terminated |
| C9040 | Injection, fremanezumab-vfrm, 1mg through FY2026 | Terminated |
| C9041 | Injection, coagulation factor xa (recombinant), inactivated (andexxa), 10 mg through FY2026 | Terminated |
| C9042 | Injection, bendamustine hcl (belrapzo), 1 mg through FY2026 | Terminated |
| C9043 | Injection, levoleucovorin, 1 mg through FY2026 | Terminated |
| C9044 | Injection, cemiplimab-rwlc, 1 mg through FY2026 | Terminated |
| C9045 | Injection, moxetumomab pasudotox-tdfk, 0.01 mg through FY2026 | Terminated |
| C9046 | Cocaine hydrochloride nasal solution (goprelto), 1 mg through FY2026 | Terminated |
| C9047 | Injection, caplacizumab-yhdp, 1 mg | Valid |
| C9048 | Dexamethasone, lacrimal ophthalmic insert, 0.1 mg through FY2026 | Terminated |
| C9049 | Injection, tagraxofusp-erzs, 10 mcg through FY2026 | Terminated |
| C9050 | Injection, emapalumab-lzsg, 1 mg through FY2026 | Terminated |
| C9051 | Injection, omadacycline, 1 mg through FY2026 | Terminated |
| C9052 | Injection, ravulizumab-cwvz, 10 mg through FY2026 | Terminated |
| C9053 | Injection, crizanlizumab-tmca, 1 mg through FY2026 | Terminated |
| C9054 | Injection, lefamulin (xenleta), 1 mg through FY2026 | Terminated |
| C9055 | Injection, brexanolone, 1mg through FY2026 | Terminated |
| C9056 | Injection, givosiran, 0.5 mg through FY2026 | Terminated |
| C9057 | Injection, cetirizine hydrochloride, 1 mg through FY2026 | Terminated |
| C9058 | Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo) 0.5 mg through FY2026 | Terminated |
| C9059 | Injection, meloxicam, 1 mg through FY2026 | Terminated |
| C9060 | Fluoroestradiol f18, diagnostic, 1 mci through FY2026 | Terminated |
| C9061 | Injection, teprotumumab-trbw, 10 mg through FY2026 | Terminated |
| C9062 | Injection, daratumumab 10 mg and hyaluronidase-fihj through FY2026 | Terminated |
| C9063 | Injection, eptinezumab-jjmr, 1 mg through FY2026 | Terminated |
| C9064 | Mitomycin pyelocalyceal instillation, 1 mg through FY2026 | Terminated |
| C9065 | Injection, romidepsin, non-lyophilized (e.g. liquid), 1mg through FY2026 | Terminated |
| C9066 | Injection, sacituzumab govitecan-hziy, 2.5 mg through FY2026 | Terminated |
| C9067 | Gallium ga-68, dotatoc, diagnostic, 0.01 mci | Valid |
| C9068 | Copper cu-64, dotatate, diagnostic, 1 millicurie through FY2026 | Terminated |
| C9069 | Injection, belantamab mafodontin-blmf, 0.5 mg through FY2026 | Terminated |
| C9070 | Injection, tafasitamab-cxix, 2 mg through FY2026 | Terminated |
| C9071 | Injection, viltolarsen, 10 mg through FY2026 | Terminated |
| C9072 | Injection, immune globulin (asceniv), 500 mg through FY2026 | Terminated |
| C9073 | Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose through FY2026 | Terminated |
| C9074 | Injection, lumasiran, 0.5 mg through FY2026 | Terminated |
| C9075 | Injection, casimersen, 10 mg through FY2026 | Terminated |
| C9076 | Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose through FY2026 | Terminated |
| C9077 | Injection, cabotegravir and rilpivirine, 2mg/3mg through FY2026 | Terminated |
| C9078 | Injection, trilaciclib, 1 mg through FY2026 | Terminated |
| C9079 | Injection, evinacumab-dgnb, 5 mg through FY2026 | Terminated |
| C9080 | Injection, melphalan flufenamide hydrochloride, 1 mg through FY2026 | Terminated |
| C9081 | Idecabtagene vicleucel, up to 460 million autologous anti-bcma car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose through FY2026 | Terminated |
| C9082 | Injection, dostarlimab-gxly, 100 mg through FY2026 | Terminated |
| C9083 | Injection, amivantamab-vmjw, 10 mg through FY2026 | Terminated |
| C9084 | Injection, loncastuximab tesirine-lpyl, 0.1 mg through FY2026 | Terminated |
| C9085 | Injection, avalglucosidase alfa-ngpt, 4 mg through FY2026 | Terminated |
| C9086 | Injection, anifrolumab-fnia, 1 mg through FY2026 | Terminated |
| C9087 | Injection, cyclophosphamide, (auromedics), 10 mg through FY2026 | Terminated |
| C9088 | Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg through FY2026 | Terminated |
| C9089 | Bupivacaine, collagen-matrix implant, 1 mg through FY2026 | Terminated |
| C9090 | Injection, plasminogen, human-tvmh, 1 mg through FY2026 | Terminated |
| C9091 | Injection, sirolimus protein-bound particles, 1 mg through FY2026 | Terminated |
| C9092 | Injection, triamcinolone acetonide, suprachoroidal (xipere), 1 mg through FY2026 | Terminated |
| C9093 | Injection, ranibizumab, via sustained release intravitreal implant (susvimo), 0.1 mg through FY2026 | Terminated |
| C9094 | Inj, sutimlimab-jome, 10 mg through FY2026 | Terminated |
| C9095 | Inj, tebentafusp-tebn, 1 mcg through FY2026 | Terminated |
| C9096 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram through FY2026 | Terminated |
| C9097 | Inj, faricimab-svoa, 0.1 mg through FY2026 | Terminated |
| C9098 | Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose through FY2026 | Terminated |
| C9101 | Injection, oliceridine, 0.1 mg | Valid |
| C9113 | Injection, pantoprazole sodium, per vial through FY2026 | Terminated |
| C9121 | Injection, argatroban, per 5 mg through FY2026 | Terminated |
| C9122 | Mometasone furoate sinus implant, 10 micrograms (sinuva) through FY2026 | Terminated |
| C9132 | Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity through FY2026 | Terminated |
| C9133 | Factor ix (antihemophilic factor, recombinant), rixubis, per i.u. through FY2026 | Terminated |
| C9134 | Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u. through FY2026 | Terminated |
| C9135 | Factor ix (antihemophilic factor, recombinant), alprolix, per i.u. through FY2026 | Terminated |
| C9136 | Injection, factor viii, fc fusion protein, (recombinant), per i.u. through FY2026 | Terminated |
| C9137 | Injection, factor viii (antihemophilic factor, recombinant) pegylated, 1 i.u. through FY2026 | Terminated |
| C9138 | Injection, factor viii (antihemophilic factor, recombinant) (nuwiq), 1 i.u. through FY2026 | Terminated |
| C9139 | Injection, factor ix, albumin fusion protein (recombinant), idelvion, 1 i.u. through FY2026 | Terminated |
| C9140 | Injection, factor viii (antihemophilic factor, recombinant) (afstyla), 1 i.u. through FY2026 | Terminated |
| C9141 | Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl (jivi), 1 i.u. through FY2026 | Terminated |
| C9142 | Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg through FY2026 | Terminated |
| C9143 | Cocaine hydrochloride nasal solution (numbrino), 1 mg | Valid |
| C9144 | Injection, bupivacaine (posimir), 1 mg | Valid |
| C9145 | Injection, aprepitant, (aponvie), 1 mg through FY2026 | Terminated |
| C9146 | Injection, mirvetuximab soravtansine-gynx, 1 mg through FY2026 | Terminated |